Foghorn Therapeutics Inc [FHTX] stock is trading at $5.29, up 11.37%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FHTX shares have gain 32.91% over the last week, with a monthly amount glided 13.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Foghorn Therapeutics Inc [NASDAQ: FHTX] stock has seen the most recent analyst activity on January 30, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $10. Previously, Jefferies started tracking the stock with Buy rating on September 03, 2024, and set its price target to $18. On August 19, 2024, Evercore ISI initiated with a Outperform rating and assigned a price target of $20 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $10 on March 28, 2023. BMO Capital Markets initiated its recommendation with a Outperform and recommended $20 as its price target on January 05, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on November 22, 2021, and assigned it a price target of $25. In a note dated November 17, 2020, Wedbush initiated an Outperform rating and provided a target price of $24 on this stock.
Foghorn Therapeutics Inc [FHTX] stock has fluctuated between $3.50 and $10.25 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Foghorn Therapeutics Inc [NASDAQ: FHTX] shares were valued at $5.29 at the most recent close of the market. An investor can expect a potential return of 164.65% based on the average FHTX price forecast.
Analyzing the FHTX fundamentals
Foghorn Therapeutics Inc [NASDAQ:FHTX] reported sales of 25.52M for the trailing twelve months, which represents a drop of -55.33%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -3.99%, Pretax Profit Margin comes in at -3.5%, and Net Profit Margin reading is -3.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is 1.68 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.85 points at the first support level, and at 4.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.96, and for the 2nd resistance point, it is at 6.63.
Ratios To Look Out For
For context, Foghorn Therapeutics Inc’s Current Ratio is 4.77. In addition, the Quick Ratio stands at 4.77 and the Cash Ratio stands at 1.02. Considering the valuation of this stock, the price to sales ratio is 11.53.
Transactions by insiders
Recent insider trading involved Costa Carlos, Chief People Officer, that happened on Sep 20 ’24 when 35756.0 shares were sold. Chief People Officer, Costa Carlos completed a deal on Sep 23 ’24 to sell 857.0 shares. Meanwhile, Chief People Officer Costa Carlos sold 11574.0 shares on Sep 18 ’24.
